While mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.

by Thomas Celona

U.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.

by Kevin McLaughlin

Women were more likely than men to have fatigue or depression linked to cancer, and both effects were linked to people withdrawing from physical activities.

by Eric Fitzsimmons

Combining an immune checkpoint inhibitor with standard care extended event-free survival by nearly two years.

by Thomas Celona

Scientists and former administrators gather for session focused on advocating for cancer research in uncertain times.

by Kevin McLaughlin

Forward Look

Immunotherapy can induce a complete response in some people with mismatch repair-deficient cancers.

by Thomas Celona

A clinical trial finds a topical gel can decrease acneiform rash and improve quality of life in people being treated for colorectal cancer.

by Thomas Celona

People with metabolic syndrome may have elevated risk for breast cancer mortality, and immunotherapy keeps lung cancer at bay even after discontinuing treatment.

by Thomas Celona

The test, which analyzes urine for 18 cancer-specific genes, ruled out the need for biopsy in men with elevated PSA without a digital rectal exam.

by Sandra Gordon

Gaps in goals-of-care discussions may harm young adults with cancer, and 1 in 6 participants in phase II trials get treatments that are eventually approved by the FDA.

by Marci A. Landsmann